Cumberland Pharmaceuticals Inc. Q1 FY2026 earnings call

• AJ Kazemi mentioned the outstanding year in 2025 with double - digit growth in sales, significant cash flow from operations, addition of a new brand to the portfolio, new international product approvals, and breakthrough clinical study results. - In 2026, there was FDA approval for expanded Caldor labeling, initiation of sales promotional efforts for Telicia, first shipment of Vibative to China, FDA clearance of the manufacturing facility for the relaunch of Vaprazole, and a transformational agreement with Apotex to integrate the branded U.S. commercial businesses. - Todd Anthony shared brand updates: Caldolor got an expanded indication and resubmitted an application to CMS for inclusion under the No Pain Act; Sancuso launched a new website; Telicia had the launch of national sales promotion; Vaprazole's manufacturing facility got FDA clearance for relaunch. - John Hamm reviewed financial results, including portfolio revenue, operating expenses, cash flow from operations, balance sheet details, and the impact of the strategic transaction on the revenue growth target

In the first quarter of 2026, Cumberland's portfolio of FDA - approved brands delivered combined revenue of $9.1 million, which represented a 5% increase after removing the one - time $3 million milestone payment last year associated with the approval of Vibatav in China. Net revenue by product for the first quarter of 2026 included $1 million for Crystalos, $2.9 million for Sancuso, $2.1 million for Vibatav, $1 million for Caldolor, and $1.9 million for Telicia

• Given the strategic transaction, Cumberland is no longer targeting double - digit revenue growth for the year. - Expenses will be significantly decreased after the closing of the transaction as Apotex will assume responsibility for sales, marketing, medical, manufacturing, and FDA fees for the brands. - Continues to advance the clinical pipeline with the new chemical entity dosed in nearly 1,400 subjects, positive Phase II results in Duchenne muscular dystrophy, fast - track designation for the fitter band candidate in DMD, and ongoing clinical programs for conditions like systemic sclerosis and idiopathic pulmonary fibrosis

Factors that could affect future results include natural disasters, economic downturns, international conflicts, trade restrictions, public health epidemics, etc., as described in the Risk Factors in Cumberland's annual report on Form 10 - K and any subsequent updates filed with the SEC

Our first question comes from Alyssa Nye from IQ Solutions. Your line is now open. Alyssa, you can ask your question. Operator, are there other questions? Yes. We'll go on to the next question. One moment, please. Our next question is Brandon Bishop. The line is now open, Brandon. The line is now open, Brandon. Operator, there appears to be difficulties with the questions coming through. There's also an echo. Yes. Let me see one second, if we can hold for a second, please. Well, since we're having difficulty hearing the questions, it's very unfortunate, but I suppose what we can do is if you would like to follow a conversation, please reach out to the company, and we're happy to schedule a call with you and to answer your questions. Meanwhile, just want to thank everybody for joining us on today's call, and we'll look forward to providing another update in the coming months. Operator? We have someone coming to fix the situation right now if we want to hold for just one second. No, that's okay. We will hold any questions. You can reach out to the company. Make sure that we can get those questions answered. Hi, everyone. I apologize. I have jumped into the queue. If you'd like, I can go over the Q&A instructions again, and I will open the lines for anyone that's gotten into the queue. That's OK. We will take our questions privately, if you don't mind. OK, absolutely. I apologize for the inconvenience. Thank you. Thank you. And this does conclude today's conference. You may now disconnect